The Rewards and Benefits on Offer: Immediate start available A highly streamlined, quick recruitment process Competitive Company pension and benefits package Ongoing training, and clear development opportunities. Free on-site parking Dayshift MTrecs New Opportunity: MTrec Technical
Location: United Kingdom – Fully Remote Employment Type: Full-time Industry: Clinical Research / CRO / Pharmaceutical The Opportunity We are supporting a well-established, international Contract Research Organisation (CRO) in the search for an experienced Clinical Data Manager
Job Title: Test Development Engineer Location: Newcastle upon Tyne – fully site-based Salary: Competitive D.O.E Benefits: Performance-related bonus, professional development and internal progression opportunities. The Company: An established specialist electronics manufacturer with a strong reputation for quality,
Job Title: Test Development Engineer Location: Newcastle upon Tyne – fully site-based Salary: Competitive D.O.E Benefits: * Performance-related bonus linked to personal and company objectives. * Structured technical support from an experienced manager. * Training in
Job Description Start here. Grow here. Our Technology Services team are looking for a Senior Technology Consultant to help deliver Intelligent Transport Systems (ITS), Connected and Automated Vehicles (CAV), Smart Cities, Mobility and all forms of technology-led
Start here. Grow here. Our Technology Services team are looking for a Senior Technology Consultant to help deliver Intelligent Transport Systems (ITS), Connected and Automated Vehicles (CAV), Smart Cities, Mobility and all forms of technology-led transport
Location: Belfast, UK; New Bailey St, Salford M3 5AX, UK; Newcastle upon Tyne, UKSalary: 45,544 - 49,523 per yearEmployment: FlexibleCategory: LegalPosted: Valid to: Employer: HM Revenue and CustomsJob summaryDiscover what it’s like to work in a
Company Description Accelerating Clinical Trials Ltd (ACT) is a not-for-profit organization focused on improving outcomes for people with blood cancer by accelerating access to clinical trials. Any surplus income is reinvested to directly benefit blood cancer